Abstract
Mobocertinib is an oral tyrosine kinase inhibitor designed to selectively target epidermal growth factor receptor (EGFR) exon 20 insertion (EGFR ex20ins) mutations in non-small cell lung cancer (NSCLC). In vitro studies indicated the potential for time-dependent inhibition and/or induction of cytochrome P450 (CYP) 3A after mobocertinib administration. Thus, a phase 1 drug-drug interaction study (NCT04051827) was conducted to assess the effect of repeat-dose administration of mobocertinib on the pharmacokinetics (PK) of midazolam, a sensitive CYP3A substrate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
